18 Aug Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
Posted at 12:07h
in
Takeda (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA), wish to inform you about the risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation of anagrelide hydrochloride.
2022 Aug
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
17/08/2022
File Type:
pdf
Category:
Communication To Health Care Professionals